Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)

This study (called PERFUME) is testing a drug called binimetinib — which targets a cell signaling pathway often activated by a BRAF gene fusion — in patients with low-grade brain tumors (glioma) or pancreatic cancer that have a BRAF gene rearrangement. This is a targeted therapy aimed at tumors with a specific genetic change. **You may be eligible if...** - You have been diagnosed with unresectable or recurrent low-grade glioma or pancreatic cancer - Your tumor has a confirmed BRAF gene fusion or rearrangement (detected by a gene panel test) - You have not received any anti-cancer drugs within the past 14 days - You do not have active or symptomatic brain spread that requires surgery or radiation **You may NOT be eligible if...** - Your tumor does not have a BRAF fusion or rearrangement - You have received anti-cancer treatment recently - You have active brain metastases requiring urgent treatment - You have significant fluid build-up (pleural effusion, ascites, or cardiac effusion) needing treatment Talk to your doctor to see if this trial is right for you.